Blanket Purchase Agreement 36F79724D0068-36E79724A0027
Award Date
8/16/24
Last Date to Order
8/15/25
Federal Agency
National Acquisition Center
Awardee
Verrica Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Verrica Pharmaceuticals Inc., a for-profit pharmaceutical company. The single-award BPA has a ceiling value of $1,250,000 and a period of performance from September 2, 2023 to August 13, 2024. The BPA is for the pharmaceutical product YCANTH, which Verrica Pharmaceuticals supplies to the VA through this contract vehicle as well as other Federal Supply Schedule (FSS)...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract under Schedule 65 IB to Verrica Pharmaceuticals Inc., a pharmaceutical company specializing in dermatology and hematology products. The FSS contract has a ceiling value of $225,000 and a period of performance through February 2029. This contract vehicle allows VA medical centers and other ordering activities to acquire qualified pharmaceutical, topical treatment, and hematology-related products directly from...
The federal contract IDV awarded to Verrica Pharmaceuticals Inc. is a Federal Supply Schedule (FSS) contract under Schedule 65 IB, with a ceiling value of $25,000 and a period of performance through February 2024. The contract, awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 12, is for pharmaceutical products including drugs, pharmaceuticals, and hematology-related items. Verrica Pharmaceuticals also holds a $1.25M Blanket Purchase Agreement (BPA) with...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Fera Pharmaceuticals, LLC, a woman-owned small business. The BPA, valued at up to $255,000, is for the procurement of Phospholine Iodide, a pharmaceutical drug. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and allows the VA and other agencies to efficiently and compliantly acquire the needed pharmaceutical product from Fera...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, which is a civilian agency under the Department of Veterans Affairs (VA), to Marius Pharmaceuticals LLC, a self-certified small disadvantaged business. The BPA has a ceiling value of $1,406.70 and a period of performance through March 2026. The purpose of this BPA is to facilitate the procurement of the pharmaceutical product KYZATREX by VA medical centers nationwide. Marius Pharmaceuticals, which holds a...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Averitas Pharma Inc., a foreign-owned, for-profit manufacturer of goods, under the Pharmaceuticals and Drugs GSA Schedule. The BPA aims to procure Qutenza, a dermatologic patch used to treat neuropathic pain, for $225,000 over a five-year period from May 2019 through March 2024. The BPA functions as an indefinite-delivery vehicle for ordering Qutenza to meet the needs of Veterans...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Vanda Pharmaceuticals Inc. (Vanda) on September 6, 2024. The BPA has a ceiling value of $3,753,465.00 and a period of performance through September 5, 2025. The primary product being procured under this BPA is Hetlioz (tasimelteon), a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis...
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Genzyme Corporation, doing business as Sanofi Genzyme. The BPA has a ceiling value of $3,000,000 and a period of performance from June 6, 2024 to June 5, 2026. The purpose of the BPA is to provide the VA with a streamlined contracting method to procure specialty pharmaceutical products,...